National Cancer Institute; Notice of Closed Meetings, 44274 [2010-18498]
Download as PDF
<![CDATA[
44274
Federal Register / Vol. 75, No. 144 / Wednesday, July 28, 2010 / Notices
Dated: July 22, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–18508 Filed 7–27–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Cancer
Institute Special Emphasis Panel,
October 21, 2010, 8 a.m. to October 21,
2010, 5 p.m., Doubletree Hotel
Bethesda, (Formerly Holiday Inn
Select), 8120 Wisconsin Avenue,
Bethesda, MD, 20814 which was
published in the Federal Register on
July 9, 2010, 75 FR 39547.
This FRN amendment has been
processed to change the location of this
meeting from the Doubletree Hotel
Bethesda, 8120 Wisconsin Avenue,
Bethesda MD 20814 to the Legacy Hotel
and Meeting Center, 1775 Rockville
Pike, Rockville MD 20852. The meeting
is closed to the public.
Dated: July 22, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–18503 Filed 7–27–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
sroberts on DSKD5P82C1PROD with NOTICES
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications
and/or contract proposals and the
discussions could disclose confidential
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications and/or contract proposals,
the disclosure of which would
constitute a clearly unwarranted
invasion of personal privacy.
VerDate Mar<15>2010
19:05 Jul 27, 2010
Jkt 220001
Name of Committee: National Cancer
Institute Special Emphasis Panel,
Nanotechnology Imaging and Sensing
Platforms for Improved Diagnosis of Cancer.
Date: August 31, 2010.
Time: 12 p.m. to 1:30 p.m.
Agenda: To review and evaluate contract
proposals.
Place: National Institutes of Health, 6116
Executive Boulevard, Room 210, Rockville,
MD 20852 (Telephone Conference Call).
Contact Person: Kenneth L. Bielat, PhD,
Scientific Review Officer, Special Review
Logistics Branch, Division of Extramural
Activities, National Cancer Institute, 6116
Executive Boulevard, Room 7147, Bethesda,
MD 20892–8329, 301–496–7576,
bielatk@mail.nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Basic,
Translational and Clinical Oncology.
Date: September 28–29, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel & Executive
Meeting Ctr. Bethesda, 8120 Wisconsin
Avenue, Bethesda, MD 20814.
Contact Person: David G. Ransom, PhD,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, NIH,
6116 Executive Blvd, Rm 8133, Bethesda, MD
20892–8328, 301–451–4757,
david.ransom@nih.gov.
Name of Committee: National Cancer
Institute Special Emphasis Panel, Drug
Discovery, Biomarkers, Therapeutics.
Date: September 28–29, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Doubletree Hotel Bethesda,
(Formerly Holiday Inn Select), 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Peter J. Wirth, PhD,
Scientific Review Officer, Research Programs
Review Branch, Division of Extramural
Activities, National Cancer Institute, 6116
Executive Boulevard, Room 8129, Bethesda,
MD 20892–8328, 301–496–7565,
pw2q@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: July 22, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–18498 Filed 7–27–10; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Use of Leptin and Leptin
Analogs for the Treatment of
Lipodystrophy
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health (NIH), Department
of Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the invention
embodied in U.S. Patent Application
No. 60/336,394, filed on October 22,
2001 (HHS Ref. No. E–064–2004/0–US–
01); PCT Application No. PCT/US02/
033875, filed on October 22, 2002 (HHS
Ref. No. E–064–2004/0–PCT–02); U.S.
Patent Application No. 10/279,129, filed
on October 22, 2002 (HHS Ref. No. E–
064–2004/0–US–03); Japanese Patent
Application No. 2003–537565, filed on
October 22, 2002 (HHS Ref. No. E–064–
2004/0–JP–04); Mexican Patent No.
250445, filed on October 22, 2002 and
granted on October 16, 2007 (HHS Ref.
No. E–064–2004/0–MX–05); Polish
Patent Application No. P–374301, filed
on October 22, 2002 (HHS Ref. No. E–
064–2004/0–PL–6); Canadian Patent
Application No. 2464277, filed on
October 22, 2002 (HHS Ref. No. E–064–
2004/0–CA–07); European Patent
Application No. 02793811.7, filed on
October 22, 2002 (HHS Ref. No. E–064–
2004/0–EP–08); U.S. Patent No.
7,183,254, filed on July 18, 2003 and
granted on 2/27/2007 (HHS Ref. No. E–
064–2004/0–US–09); U.S. Patent
Application No. 11/606,805, filed on
October 29, 2006 (HHS Ref. No. E–064–
2004/0–US–10); Mexican Patent
Application No. 2007/006095, filed on
May 14, 2007 (HHS Ref. No. E–064–
2004/0–MX–11); Australian Patent
Application No. 2002359288, filed on
October 22, 2002 (HHS Ref. No. E–064–
2004/0–AU–12); Hong Kong Patent
Application No. 4106574.7, filed on
September 1, 2004 (HHS Ref. No. E–
064–2004/0–HK–13); European Patent
Application No. 10165256.8, filed on
June 8, 2010 (HHS Ref. No. E–064–2004/
0–EP–14); and Japanese Patent
Application No. 2010–137501, filed on
June 16, 2010 (HHS Ref. No. E–064–
2004/0–JP–15), all entitled ‘‘Use of
Leptin for Treating Human Lipoatrophy
and Method of Determining
Predisposition to Said Treatment’’, to
SUMMARY:
E:\FR\FM\28JYN1.SGM
28JYN1
]]>Agencies
[Federal Register Volume 75, Number 144 (Wednesday, July 28, 2010)]
[Notices]
[Page 44274]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-18498]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Cancer Institute Special Emphasis
Panel, Nanotechnology Imaging and Sensing Platforms for Improved
Diagnosis of Cancer.
Date: August 31, 2010.
Time: 12 p.m. to 1:30 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, 6116 Executive Boulevard,
Room 210, Rockville, MD 20852 (Telephone Conference Call).
Contact Person: Kenneth L. Bielat, PhD, Scientific Review
Officer, Special Review Logistics Branch, Division of Extramural
Activities, National Cancer Institute, 6116 Executive Boulevard,
Room 7147, Bethesda, MD 20892-8329, 301-496-7576,
bielatk@mail.nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel, Basic, Translational and Clinical Oncology.
Date: September 28-29, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Doubletree Hotel & Executive Meeting Ctr. Bethesda, 8120
Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: David G. Ransom, PhD, Scientific Review Officer,
Research Programs Review Branch, Division of Extramural Activities,
National Cancer Institute, NIH, 6116 Executive Blvd, Rm 8133,
Bethesda, MD 20892-8328, 301-451-4757, david.ransom@nih.gov.
Name of Committee: National Cancer Institute Special Emphasis
Panel, Drug Discovery, Biomarkers, Therapeutics.
Date: September 28-29, 2010.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Doubletree Hotel Bethesda, (Formerly Holiday Inn Select),
8120 Wisconsin Avenue, Bethesda, MD 20814.
Contact Person: Peter J. Wirth, PhD, Scientific Review Officer,
Research Programs Review Branch, Division of Extramural Activities,
National Cancer Institute, 6116 Executive Boulevard, Room 8129,
Bethesda, MD 20892-8328, 301-496-7565, pw2q@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: July 22, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-18498 Filed 7-27-10; 8:45 am]
BILLING CODE 4140-01-P
